Novel diagnostic and prognostic biomarkers and molecular therapeutic targets in aggressive, metastatic and recurrent melanomas

Murielle Mimeault, Surinder Kumar Batra

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Cutaneous melanomas are the malignant and aggressive tumors of skin with extremely poor survival rates for the patients diagnosed with locally invasive and metastatic disease stages. Despite intensive research has led in last few years to an improvement of the curative treatment of early-stage cutaneous melanomas by tumor surgical resection, ionizing radiation, systemic chemotherapy, immunotherapy and/or adjuvant stem cell-based therapies, the locally advanced and disseminated melanomas are generally resistant to conventional therapies and result to the death of cancer patients. The rapid progression of primary melanomas to locally invasive and/or metastatic disease stages remains a major obstacle for an early effective diagnosis and a curative therapeutic intervention for melanoma patients. Importantly, recent advances in the melanoma research have led to the identification of different gene products that are frequently implicated in the malignant transformation of melanocytic cells into melanoma cells, including melanoma stem/progenitor cells, during cancer initiation and progression to locally advanced and metastatic disease stages. These oncogenic events include the occurrence of activating mutations in distinct oncogenes such as v-Raf murine sarcoma viral oncogene homolog B1 (B-RAF) or neuroblastoma RAS viral oncogene homolog (N-Ras). The enhanced expression and activities of diverse growth factor signaling elements such as epidermal growth factor receptor (EGFR), sonic hedgehog, Wnt/β-catenin, Notch and vascular endothelial growth factor (VEGF)/VEGF-R receptors in melanoma cells also represent common molecular events associated with melanoma progression, metastases at distant sites, treatment resistance and disease relapse. Of therapeutic relevance, these deregulated signaling transduction components constitute new potential biomarkers and therapeutic targets of great clinical interest for improving the efficacy of current diagnostic and prognostic methods and management of patients diagnosed with locally advanced, metastatic and/or relapsed melanomas.

Original languageEnglish (US)
Title of host publicationMetastatic Melanoma
Subtitle of host publicationSymptoms, Diagnoses and Treatments
PublisherNova Science Publishers, Inc.
Pages127-148
Number of pages22
ISBN (Print)9781612099156
StatePublished - Apr 1 2011

Fingerprint

Biomarkers
Melanoma
Stem cells
Vascular Endothelial Growth Factor A
Tumors
Catenins
Chemotherapy
Ionizing radiation
Therapeutics
Epidermal Growth Factor Receptor
Stem Cells
Intercellular Signaling Peptides and Proteins
Skin
Oncogenes
Genes
Cells
Neoplasms
Vascular Endothelial Growth Factor Receptor
Disease Resistance
ras Genes

Keywords

  • Angiogenesis
  • Cancer therapy
  • Cutaneous melanomas
  • Diagnosis
  • Drug resistance
  • Growth factors
  • Invasion
  • Melanoma cells
  • Melanoma stem/progenitor cells
  • Metastases
  • Molecular targeting
  • Prognosis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Mimeault, M., & Batra, S. K. (2011). Novel diagnostic and prognostic biomarkers and molecular therapeutic targets in aggressive, metastatic and recurrent melanomas. In Metastatic Melanoma: Symptoms, Diagnoses and Treatments (pp. 127-148). Nova Science Publishers, Inc..

Novel diagnostic and prognostic biomarkers and molecular therapeutic targets in aggressive, metastatic and recurrent melanomas. / Mimeault, Murielle; Batra, Surinder Kumar.

Metastatic Melanoma: Symptoms, Diagnoses and Treatments. Nova Science Publishers, Inc., 2011. p. 127-148.

Research output: Chapter in Book/Report/Conference proceedingChapter

Mimeault, M & Batra, SK 2011, Novel diagnostic and prognostic biomarkers and molecular therapeutic targets in aggressive, metastatic and recurrent melanomas. in Metastatic Melanoma: Symptoms, Diagnoses and Treatments. Nova Science Publishers, Inc., pp. 127-148.
Mimeault M, Batra SK. Novel diagnostic and prognostic biomarkers and molecular therapeutic targets in aggressive, metastatic and recurrent melanomas. In Metastatic Melanoma: Symptoms, Diagnoses and Treatments. Nova Science Publishers, Inc. 2011. p. 127-148
Mimeault, Murielle ; Batra, Surinder Kumar. / Novel diagnostic and prognostic biomarkers and molecular therapeutic targets in aggressive, metastatic and recurrent melanomas. Metastatic Melanoma: Symptoms, Diagnoses and Treatments. Nova Science Publishers, Inc., 2011. pp. 127-148
@inbook{da017a4c567044b2ae1bb5a696f50c86,
title = "Novel diagnostic and prognostic biomarkers and molecular therapeutic targets in aggressive, metastatic and recurrent melanomas",
abstract = "Cutaneous melanomas are the malignant and aggressive tumors of skin with extremely poor survival rates for the patients diagnosed with locally invasive and metastatic disease stages. Despite intensive research has led in last few years to an improvement of the curative treatment of early-stage cutaneous melanomas by tumor surgical resection, ionizing radiation, systemic chemotherapy, immunotherapy and/or adjuvant stem cell-based therapies, the locally advanced and disseminated melanomas are generally resistant to conventional therapies and result to the death of cancer patients. The rapid progression of primary melanomas to locally invasive and/or metastatic disease stages remains a major obstacle for an early effective diagnosis and a curative therapeutic intervention for melanoma patients. Importantly, recent advances in the melanoma research have led to the identification of different gene products that are frequently implicated in the malignant transformation of melanocytic cells into melanoma cells, including melanoma stem/progenitor cells, during cancer initiation and progression to locally advanced and metastatic disease stages. These oncogenic events include the occurrence of activating mutations in distinct oncogenes such as v-Raf murine sarcoma viral oncogene homolog B1 (B-RAF) or neuroblastoma RAS viral oncogene homolog (N-Ras). The enhanced expression and activities of diverse growth factor signaling elements such as epidermal growth factor receptor (EGFR), sonic hedgehog, Wnt/β-catenin, Notch and vascular endothelial growth factor (VEGF)/VEGF-R receptors in melanoma cells also represent common molecular events associated with melanoma progression, metastases at distant sites, treatment resistance and disease relapse. Of therapeutic relevance, these deregulated signaling transduction components constitute new potential biomarkers and therapeutic targets of great clinical interest for improving the efficacy of current diagnostic and prognostic methods and management of patients diagnosed with locally advanced, metastatic and/or relapsed melanomas.",
keywords = "Angiogenesis, Cancer therapy, Cutaneous melanomas, Diagnosis, Drug resistance, Growth factors, Invasion, Melanoma cells, Melanoma stem/progenitor cells, Metastases, Molecular targeting, Prognosis",
author = "Murielle Mimeault and Batra, {Surinder Kumar}",
year = "2011",
month = "4",
day = "1",
language = "English (US)",
isbn = "9781612099156",
pages = "127--148",
booktitle = "Metastatic Melanoma",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Novel diagnostic and prognostic biomarkers and molecular therapeutic targets in aggressive, metastatic and recurrent melanomas

AU - Mimeault, Murielle

AU - Batra, Surinder Kumar

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Cutaneous melanomas are the malignant and aggressive tumors of skin with extremely poor survival rates for the patients diagnosed with locally invasive and metastatic disease stages. Despite intensive research has led in last few years to an improvement of the curative treatment of early-stage cutaneous melanomas by tumor surgical resection, ionizing radiation, systemic chemotherapy, immunotherapy and/or adjuvant stem cell-based therapies, the locally advanced and disseminated melanomas are generally resistant to conventional therapies and result to the death of cancer patients. The rapid progression of primary melanomas to locally invasive and/or metastatic disease stages remains a major obstacle for an early effective diagnosis and a curative therapeutic intervention for melanoma patients. Importantly, recent advances in the melanoma research have led to the identification of different gene products that are frequently implicated in the malignant transformation of melanocytic cells into melanoma cells, including melanoma stem/progenitor cells, during cancer initiation and progression to locally advanced and metastatic disease stages. These oncogenic events include the occurrence of activating mutations in distinct oncogenes such as v-Raf murine sarcoma viral oncogene homolog B1 (B-RAF) or neuroblastoma RAS viral oncogene homolog (N-Ras). The enhanced expression and activities of diverse growth factor signaling elements such as epidermal growth factor receptor (EGFR), sonic hedgehog, Wnt/β-catenin, Notch and vascular endothelial growth factor (VEGF)/VEGF-R receptors in melanoma cells also represent common molecular events associated with melanoma progression, metastases at distant sites, treatment resistance and disease relapse. Of therapeutic relevance, these deregulated signaling transduction components constitute new potential biomarkers and therapeutic targets of great clinical interest for improving the efficacy of current diagnostic and prognostic methods and management of patients diagnosed with locally advanced, metastatic and/or relapsed melanomas.

AB - Cutaneous melanomas are the malignant and aggressive tumors of skin with extremely poor survival rates for the patients diagnosed with locally invasive and metastatic disease stages. Despite intensive research has led in last few years to an improvement of the curative treatment of early-stage cutaneous melanomas by tumor surgical resection, ionizing radiation, systemic chemotherapy, immunotherapy and/or adjuvant stem cell-based therapies, the locally advanced and disseminated melanomas are generally resistant to conventional therapies and result to the death of cancer patients. The rapid progression of primary melanomas to locally invasive and/or metastatic disease stages remains a major obstacle for an early effective diagnosis and a curative therapeutic intervention for melanoma patients. Importantly, recent advances in the melanoma research have led to the identification of different gene products that are frequently implicated in the malignant transformation of melanocytic cells into melanoma cells, including melanoma stem/progenitor cells, during cancer initiation and progression to locally advanced and metastatic disease stages. These oncogenic events include the occurrence of activating mutations in distinct oncogenes such as v-Raf murine sarcoma viral oncogene homolog B1 (B-RAF) or neuroblastoma RAS viral oncogene homolog (N-Ras). The enhanced expression and activities of diverse growth factor signaling elements such as epidermal growth factor receptor (EGFR), sonic hedgehog, Wnt/β-catenin, Notch and vascular endothelial growth factor (VEGF)/VEGF-R receptors in melanoma cells also represent common molecular events associated with melanoma progression, metastases at distant sites, treatment resistance and disease relapse. Of therapeutic relevance, these deregulated signaling transduction components constitute new potential biomarkers and therapeutic targets of great clinical interest for improving the efficacy of current diagnostic and prognostic methods and management of patients diagnosed with locally advanced, metastatic and/or relapsed melanomas.

KW - Angiogenesis

KW - Cancer therapy

KW - Cutaneous melanomas

KW - Diagnosis

KW - Drug resistance

KW - Growth factors

KW - Invasion

KW - Melanoma cells

KW - Melanoma stem/progenitor cells

KW - Metastases

KW - Molecular targeting

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84895215699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895215699&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84895215699

SN - 9781612099156

SP - 127

EP - 148

BT - Metastatic Melanoma

PB - Nova Science Publishers, Inc.

ER -